AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms
Aspergillus is a filamentous mould ubiquitous in the environment and the concentration of its spores in the air varies according to weather conditions and seasons. In this regard, efforts are often made to limit its diffusion in wards where fragile patients are housed (e.g., ICU, Haematology, Oncology, etc.). Indeed, in these patients, Aspergillus infections can present as pulmonary aspergillosis, invasive rhinosinusitis or angio-invasive aspergillosis with significantly high rates of morbidity and mortality, while it rarely causes disease in healthy immunocompetent subjects. Previous studies have established the correlation between nasal carriage of microorganisms and the development of an invasive infectious disease; however, those studies mainly focused on Staphylococci and Candida species. The main target of this study is to investigate the spread of Aspergillus within a hospital w
Sign in to get the eligibility rules as simple questions to take to your doctor.
AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy